In Vitro Metabolic Stability and Intestinal Transport of P57AS3 (P57) from Hoodia gordonii and its Interaction with Drug Metabolizing Enzymes

Abstract

Hoodia gordonii, a succulent cactus-like plant growing in South Africa, has been used in traditional medicine for its appetite suppressant properties. Its use as a dietary supplement to promote weight loss has recently gained popularity. An oxypregnane steroidal glycoside P57AS3 (P57) is reported to be the active constituent of the sap extract responsible for anorexigenic activity. No information is available about its metabolic stability, intestinal transport and interaction with drug metabolizing enzymes. In the present investigation, the metabolic stability of P57 in human liver microsomes and its interaction with drug metabolizing enzymes (CYP1A2, 2C9, 3A4 and 2D6) were determined. Intestinal transport of P57 was studied in the Caco-2 cell model of intestinal transport and absorption. P57 was metabolically stable in the presence of human liver microsomes. The compound inhibited CYP3A4 activity with an IC₅₀ value of 45 μM, whereas the activity of CYP 1A2, 2C9 and 2D6 was not inhibited. In the Caco-2 model, P57 exhibited a higher transport in the secretory direction than in the absorptive direction with efflux ratios of 3.1 and 3.8 at 100 and 200 μM, respectively. The efflux was inhibited by selective inhibitors of multidrug resistance associated proteins MRP1/MRP2 (MK-571) and P-gp (verapamil). In conclusion, intestinal transport of P57 was mediated by P-gp and MRP transporters. The compound was metabolically stable and showed weak inhibition of CYP 3A4.

Abbreviations

Caco-2:human colonic adenocarcinoma

CYP:cytochrome P450

H. gordonii:Hoodia gordonii

Ly:Lucifer yellow

MRP:multidrug resistance-associated protein

P57AS3:P57

Papp:apparent permeability

P-gp:P-glycoprotein

TEER:transepithelial electrical resistance

Key words

Hoodia gordonii - Asclepiadaceae - P57 - metabolic stability - CYP inhibition - intestinal transport

References

• 1 South African National Biodiversity Institute. Plants of Southern Africa. Available at http://www.plantzafrica.com. Accessed March 14, 2008
• 2 Rubin D I, Cathorne M H, Bindra J S. Extracts, compounds and pharmaceutical compositions having anti-diabetic activity and their use. Eur Pat EP1166792 2002
• 3 Pawar R S, Shukla Y J, Khan S I, Avula B, Khan I A. New oxypregnane glycosides from appetite suppressant herbal supplement Hoodia gordonii.  Steroids. 2007;  72 524-34
• 4 Van Heerden F R, Horak R M, Maharaj V J, Vleggaar R, Senabe J V, Gunning P J. An appetite suppressant from Hoodia species.  Phytochemistry. 2007;  68 2545-53
• 5 Maclean D B, Luo L G. Increased ATP content/production in the hypothalamus may be a signal for energy-sensing or satiety: studies on anorectic mechanism of a plant steroidal glycoside.  Brain Res. 2004;  1020 1-11
• 6 Food and Drug Administration. Drug interaction studies: study design data analysis, and implications for dosing and labelling. CDER, Department of Health and Human Services, CBER, FDA 2004
• 7 Yi W, Akoh C C, Fischer J, Krewer G. Absorption of anthocyanins from blueberry extracts by Caco-2 human intestinal epithelial cell monolayers.  J Agric Food Chem. 2006;  54 5651-8
• 8 Artursson P, Palm K, Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport.  Adv Drug Delivery Rev. 1996;  22 67-84
• 9 Madgula V L, Avula B, Reddy N V, Khan I A, Khan S I. Transport of decursin and decursinol angelate across Caco-2 and MDR-MDCK cell monolayers: In vitro models for intestinal and blood-brain barrier permeability.  Planta Med. 2007;  73 330-5
• 10 Khan S I, Abourashed E A, Khan I A, Walker L A. Transport of harman alkaloids across Caco-2 cell monolayers.  Chem Pharm Bull. 2004;  52 394-7
• 11 Sambuy Y, De Angelis I, Ranaldi G, Scarino M L, Stammati A, Zucco F. The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics.  Cell Biol Toxicol. 2005;  21 1-26
• 12 Hidalgo I J, Jibin L. Carrier-mediated transport and efflux mechanisms in Caco-2 cells.  Adv Drug Deliv Res. 1996;  22 53-66
• 13 Crespi C L, Miller V P, Penman B W. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450.  Anal Biochem. 1997;  248 188-90
• 14 Obach R S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and non-specific binding to microsomes.  Drug Metab Dispos. 1999;  27 1350-9
• 15 Obach R S, Baxter J G, Listen T E, Silber B M, Jones B C, MacIntyre F. et al . Prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data.  J Pharmacol Exp Ther. 1997;  283 46-58
• 16 Usia T, Iwata H, Hiratsuka A, Watabe T, Kadota S, Tezuka Y. CYP3A4 and CYP 2D6 activities of Indonesian medicinal plants.  Phytomedicine. 2006;  13 67-73
• 17 Liu Y, Yang L. Early metabolism evaluation making Traditional Chinese Medicine effective and safe therapeutics.  J Zhejiang Univ Sci B. 2006;  7 99-106
• 18 Barone G W, Gurley B J, Ketel B L, Lightfoot M L, Abul-Ezz S R. Drug interactions between St. John’s wort and cyclosporine.  Ann Pharmacother. 2000;  34 239-55
• 19 Rosenblatt M, Mindel J. Spontaneous hyphema associated with the ingestion of Ginkgo biloba extract.  New Engl J Med. 1997;  336 1108
• 20 Gutmann H, Fricker G, Torok M, Michael S, Beglinger C, Drewe J. Evidence for different ABC – transporters in Caco-2 cells modulating drug uptake.  Pharm Res. 1999;  16 402-7
• 21 Hirohashi T, Suzuki H, Chu X Y, Tamai I, Tsuji A, Sugiyama Y. Function and expression of multidrug resistance-associated protein family in human colon adenocarcinoma cells (Caco-2).  J Pharmacol Exp Ther. 2000;  295 265-70
• 22 Tian X, Yang X, Wang K, Yang X. The efflux of flavonoids morin, isorhamnetin-3-O-rutinoside and diosmetin-7-O-beta-D-xylopyranosyl-(1 – 6)-beta-D-glucopyranoside in the human intestinal cell line Caco-2.  Pharm Res. 2006;  23 1721-8
• 23 Hilgendorf C, Ahlin J, Seithal A, Artursson P, Ungell A L, Karlson J. Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines.  Drug Metab Dispos. 2007;  35 1333-40
• 24 Cao J, Chen X, Liang J, Yu X Q, Xu A L, Chan E. et al . Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid from the root of Glycyrrhiza glabra.  Drug Metab Dispos. 2007;  35 539-53
• 25 Walgren R A, Karnaky JK J r, Lindenmayer G E, Walle T. Efflux of dietary flavonoids quercetin 4’β-glucoside across human intestinal Caco-2 cell monolayers by apical multidrug resistance-associated protein-2.  J Pharmacol Exp Ther. 2000;  294 830-6
• 26 Tsuruo T, Lida S, Tsukagoshi T, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil.  Cancer Res. 1981;  41 1967-72
• 27 Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development.  Pharmacol Rev. 2003;  55 425-61